Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 14/20 | 0.40 |
| ▸ | EGLN1 | Q9GZT9 | 12/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25194482 | 1.00 | EGLN2 (0.40) | EGLN2EGLN1AKR1C3NAMPTESR1 | |
| SCHEMBL30121002 | 0.85 | ERAP1 (0.35) | EGLN1NAMPTESR1CNR1CNR2 | |
| SCHEMBL23896092 | 0.85 | EGLN1 (0.48) | EGLN2EGLN1NAMPT | |
| SCHEMBL23887791 | 0.85 | ERAP1 (0.35) | EGLN1NAMPTESR1CNR1CNR2 | |
| SCHEMBL23887713 | 0.84 | EGLN1 (0.42) | EGLN2EGLN1NAMPTESR1HDAC1 | |
| SCHEMBL23896091 | 0.83 | EGLN2 (0.50) | EGLN2EGLN1 | |
| SCHEMBL30367797 | 0.83 | ESR1 (0.40) | NAMPTESR1HDAC1HDAC2PRKAA2 | |
| SCHEMBL23887827 | 0.83 | ESR1 (0.40) | NAMPTESR1HDAC1HDAC2PRKAA2 | |
| SCHEMBL23896358 | 0.82 | ULK1 (0.36) | EGLN2EGLN1NAMPTESR1 | |
| SCHEMBL25544067 | 0.82 | NAMPT (0.37) | EGLN2EGLN1NAMPTESR1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126819-A1 | 7- OR 8-HYDROXY-ISOQUINOLINE AND 7- OR 8-HYDROXY-QUINOLINE DERIVATIVES AS ALPHA-1 -ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1 -ANTITRYPSIN DEFICIENCY (AATD) | Vertex Pharmaceuticals Incorporated (US) | 2023-02-08 | — | — | EP | disclosed |